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Abstract
O-linked glycosylation is a ubiquitous protein modification in organisms belonging to several
kingdoms. Both microbial and host protein glycans are used by many pathogens for host
invasion and immune evasion, yet little is known about the roles of O-glycans in viral patho-
genesis. Reportedly, there is no single function attributed to O-glycans for the significant
paramyxovirus family. The paramyxovirus family includes many important pathogens, such
as measles, mumps, parainfluenza, metapneumo- and the deadly Henipaviruses Nipah
(NiV) and Hendra (HeV) viruses. Paramyxoviral cell entry requires the coordinated actions
of two viral membrane glycoproteins: the attachment (HN/H/G) and fusion (F) glycoproteins.
O-glycan sites in HeV G were recently identified, facilitating use of the attachment protein of
this deadly paramyxovirus as a model to study O-glycan functions. We mutated the identi-
fied HeV G O-glycosylation sites and found mutants with altered cell-cell fusion, G confor-
mation, G/F association, viral entry in a pseudotyped viral system, and, quite unexpectedly,
pseudotyped viral F protein incorporation and processing phenotypes. These are all impor-
tant functions of viral glycoproteins. These phenotypes were broadly conserved for equiva-
lent NiV mutants. Thus our results identify multiple novel and pathologically important
functions of paramyxoviral O-glycans, paving the way to study O-glycan functions in other
paramyxoviruses and enveloped viruses.
Author Summary
Glycosylation is a protein modification process that occurs inside cells, in which specific
types of sugars (glycans) are added to certain amino acids in some proteins. Glycosylation
happens for many organisms, from microbes to mammals, including many pathogens.
Altered glycosylation is increasingly being associated with auto-immune diseases and can-
cer, highlighting the need to better understand glycosylation. There are two types of sugars
added during the glycosylation process: N-glycans and O-glycans. While the roles of N-
glycans have been extensively reported for many organisms, the roles of O-glycans remain
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largely unknown, particularly for viruses. The paramyxoviruses are a medically important
family of viruses that include the highly lethal Hendra (HeV) and Nipah (NiV) viruses.
Viral entry into host cells and spread from cell to cell relies on two viral proteins: G and F.
Here we mutated known O-glycan locations in the HeV and NiV G proteins. Loss of O-
glycans affected several viral processes crucial to viral entry and spread from cell to cell.
Our results are the first reported functions for paramyxoviral O-glycans, contributing to
the field of viral entry and spread, and helping pave the way for future functional studies
in other pathogens.
Introduction
Many microbial pathogens utilize protein glycosylation for host invasion and immune evasion
[1]. Although many N-glycan functions have been reported, relatively little is known about the
roles of O-glycans in microbial pathogenesis or biology, particularly for viruses. O-linked gly-
cosylation is a ubiquitous protein modification in organisms belonging to several kingdoms.
For example, O-glycans play roles in protein trafficking, signaling, cell-cell interactions, and
receptor binding for host proteins [2–4], and O-glycans are important for developmental pro-
cesses and immune system functions [3]. Additionally, altered O-glycosylation has been linked
to illnesses such as autoimmune diseases and cancer [5–7], as well as pathogen virulence [8–
10]. Yet currently the specific functions of O-glycans on viral glycoproteins are not well under-
stood, and to our knowledge there is no single function attributed to O-glycans for the impor-
tant paramyxovirus family.
Conversely, viral glycoprotein N-glycans are known to be critical for proper protein folding
and trafficking, receptor interactions, cell adhesion, and evasion of host immune responses
[reviewed in [1]]. In addition, loss of paramyxoviral N-glycans reduces or increases membrane
fusion capacity and processing of the F glycoproteins of measles virus (MeV), NiV, and Sendai
virus [11–13], and N glycans on NiV F and G modulate membrane fusion and viral infectivity,
and protect the virus from antibody neutralization [12,14–17]. Additionally, galectin-1, a lectin
that binds specific N-glycans and O-glycans, inhibits NiV cell-cell fusion when added post-
infection, but can enhance viral entry into endothelial cells by increasing viral attachment to
target cells [18–20].
While potential N-glycosylation sites are marked by a distinctive N-X-S/T motif (where N is
asparagine, X is any residue except proline, S is serine, and T is threonine), the determinants
that cause addition of O-glycans to S or T residues are incompletely understood. Moreover, O-
glycosylation of one S or T can affect O-glycosylation of other S or T residues [21]. O-glycans
can act as an antibody shield for the gammaherpesvirus bovine herpes virus (BoHV-4) [22],
affect binding of herpes simplex virus 1 (HSV1) gB to the paired immunoglobulin-like type 2
receptor alpha (PILRα) receptor and hence PILRα-dependent viral entry [23,24], and O-gly-
cans on HSV1 gC-1 are thought to affect receptor binding and cell-cell spread [25]. For HSV-2,
viral O-glycans have been recently shown to stimulate an antiviral immune response upstream
from interferons [26]. Additionally, an O-glycan-rich region of Ebola virus GP plays a role in
cell detachment [27], though this function has yet to be linked directly to the O-glycans them-
selves. O-glycans are present on the human immunodeficiency virus (HIV) and simian immu-
nodeficiency virus (SIV) envelope, Marburg spike protein, mouse hepatitis virus (MHV) E1
protein, and vaccinia hemagglutinin (HA) [28–32], but the functions of these O-glycans are
unknown. For the paramyxoviruses, it is known that O-glycans are not involved in respiratory
syncytial virus (RSV) G oligomerization [33] nor Newcastle disease virus (NDV) receptor
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binding [34]. To our knowledge, however, no study has reported any functions for paramyxo-
viral O-glycans.
The Paramyxoviridae family is comprised of negative-sense single-stranded enveloped
RNA viruses including measles (MeV), respiratory syncytial (RSV), Newcastle disease (NDV),
parainfluenza (PIV), metapneumo- (MPV), and the deadly Henipaviruses (HNV) NiV and
HeV among others [35]. HeV and NiV are biosafety level 4 (BSL4) pathogens with no
approved vaccine or treatment for humans. Individuals infected with NiV or HeV suffer from
respiratory distress and encephalitis, with 40–90% mortality rates [36]. A hallmark of HNV
viral infections is extensive formation of syncytia (cell-cell fusion). These viruses can be trans-
mitted from animal-to-animal, animal-to-human and human-to-human [37], highlighting a
need for understanding the mechanism of HNV spread between individuals and within
infected individuals.
Paramyxoviruses use two transmembrane glycoproteins to facilitate both viral-cell fusion
during viral entry, and the pathognomonic syncytia formation. The attachment (H, G, or HN)
protein binds the cell receptor, in turn activating the fusion protein (F) to insert its hydropho-
bic fusion peptide into the host cell membrane and execute viral-cell membrane fusion, result-
ing in viral entry into the host cell [38]. Via a similar mechanism, F and H/G/HN also cause
cell-cell fusion of infected-healthy cells. For HNV, the attachment protein G binds the cell
receptor ephrinB2 or ephrinB3 [39–41]. HNV G consists of an N-terminal cytoplasmic tail fol-
lowed by a transmembrane region, a stalk domain, and a C-terminal globular head (Fig 1A),
responsible for receptor binding [42].
The H/G/HN stalk plays an important role in paramyxovirus-induced membrane fusion,
executed by the F glycoprotein. Disrupting the H/G/HN stalk inhibits fusion [43–45], and
headless mutants are capable of causing fusion, underlining that the stalk itself is key in the
fusion triggering process [46–49]. Recently, multiple specific O-glycan structures in a stalk
domain of HeV G were identified [50], but the functions of these O-glycans are unknown.
Since the HeV G stalk plays an important role in viral-cell and cell-cell membrane fusion, and
O-glycan structural data is available for HeV, we used HeV G as a model to investigate the
functions of O-glycans in henipaviral and paramyxoviral biology.
We mutated each O-glycosylated Ser or Thr in the heavily O-glycosylated HeV G stalk
domain 103–137 to alanine (Ala), to prevent O-glycosylation at specific sites on the protein.
Loss of these O-glycans affected membrane fusion levels, resulting in both hyper- and hypo-
fusogenic phenotypes. Multiple mutants displayed altered HeV G/F association, viral entry
capabilities in a pseudotyped virus system, and F incorporation into pseudotyped virions, and
one mutant had an altered conformation and altered receptor-induced conformational changes
important for membrane fusion. Furthermore, equivalent mutants in NiV G displayed highly-
conserved roles, with most mutants replicating the HeV phenotypes, although some distinct
photypes were observed for NiV, suggesting overall high conservation of O-glycan functions
for this genus. This study is the first to uncover multiple functions of O-glycans in the para-
myxovirus family, identifies the highest number of functions of O-glycans for any single virus,
and points to differences between N- and O-glycan functions for the paramyxoviruses.
Results
O-glycans in the HNV G stalk domain modulate membrane fusion
The specific locations and structures of O-glycans in HeV G have been identified via mass
spectrometry [50], and except for one, all were found in the stalk. We mutated each O-glycosy-
lated S or T residue in the heavily O-glycosylated stalk domain 103–137 to an alanine (A) to
prevent O-glycosylation at each specific site (Fig 1A). Multiple adjacent O-glycosylation sites
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were mutated simultaneously to limit the number of target mutants, thus we initially con-
structed nine mutants. The S116A-T117A double mutant was then split into two single
mutants, S116A and T117A, respectively, for a total of eleven mutants.
We first tested the ability of the mutant HeV G proteins to induce cell-cell fusion. For con-
sistency, we used 293T cells to provide a similar cell background as that used for the HeV G O-
glycan structural studies by Colgrave et. al. [50]. 293T cells were transfected with wild-type
(wt) HeV F and either wt HeV G or an O-glycan mutant. After 18–24 hours post-transfection,
nuclei in syncytia (fused cells) were quantified microscopically, with a syncytium defined as
four or more nuclei within a single cell membrane, and compared to the wt G [49]. Interest-
ingly, five of the eleven mutants showed differences in cell-cell fusion, with reduced fusion lev-
els for T103A and T119A (2% and 0%, respectively) and increased fusion for T117A,
S116-T117A, and S129A (232–316%). These mutants are the first to show that viral O-glycans
can have an effect on modulating the extent of cell-cell fusion (Fig 1B). Interestingly the single
mutant S116A did not yield an altered fusion phenotype, suggesting that the hyper-fusogeni-
city of the S116A-T117A double mutant is largely due to the S117A substitution (Fig 1B).
We then used flow cytometry to ask if these fusion phenotypes were due to altered cell sur-
face expression (CSE) levels of the mutant HeV G proteins. 293T cells transfected with either
wt or mutant G plasmids were collected 18–24 hours post-transfection and stained with a 1°
antibody to the extracellular C-terminal hemagglutinin (HA) tag in the proteins, to avoid false
Fig 1. O-glycans on the HNVG stalk modulate fusion. A) Schematic of the HNV G protein. The dashed
lines denote the O-glycan rich region in which mutants were created, with the insert showing the amino acid
sequence of that region. Amino acids determined by mass spectrometry to be O-glycosylated in HeV are in
bold. CT = cytoplasmic tail, TM = transmembrane. B&D) Cell surface expression (CSE, white) fusion (black),
and ephrinB2 binding (grey) levels of generated HeV G (B) or NiV G (D) mutants. All values were normalized
to wt HeV or NiV G. Averages and standard deviations are shown. N = 5. Statistically significant differences,
as determined by a Student’s t-test, are marked with an * (p< 0.05). C, E) Western blot analysis of cell lysates
from HeVG (C) or NiV G (E) mutants.
doi:10.1371/journal.ppat.1005445.g001
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conformational influences on the mutant’s real CSE levels, followed by a fluorescent 2° anti-
body. CSE of mutant HeV G proteins were normalized to the values of wt HeV G. All mutants
were expressed at the cell surface at levels comparable to that of wt HeV G (87–115%, Fig 1B).
Normalized fusion levels were then divided by normalized CSE values to obtain a fusion index,
with hyperfusogenic mutants defined as having a fusion index1.5, and hypofusogenic
mutants having a fusion index0.5 (Table 1) [14]. All mutants also bound soluble B2-hFC as
detected by flow cytometry at levels similar to their respective CSE values (Fig 1B), which is
expected since the G head, not the stalk, is responsible for ephrinB2 binding [42,51]. These
results suggest that the mutants’ altered membrane fusion capabilities were not due to differ-
ences in CSE or receptor binding. In addition, Western blot analysis using an anti-HA antibody
confirmed that all mutants were expressed in cell lysates (Fig 1C).
The stalk domains of HeV and NiV are highly conserved, with 90% amino acid identity
between the two. After observing that loss of O-glycans in HeV G affected cell-cell fusion, we
created equivalent mutants in NiV G. Thus we generated the same eleven NiV G mutants, with
the exception of the HeV G double mutant S136A-S137A, which became a single mutant S137A
in NiV, as residue 136 in wt NiV is already an alanine. Remarkably, we observed very similar
overall fusion phenotypes for NiV, with the T103A and T119Amutants being hypo-fusogenic
(6% and 0% fusion, respectively) and T117A, S116A-T117A, and S129A being hyper-fusogenic
(212–350% fusion). CSE levels for these mutants were similar to HeV as well, with the exception
that T119A expressed at the cell surface at only ~36% in NiV compared to ~87% in HeV, and
S110A did not express at all for NiV (Fig 1D). Fusion indices for the NiV G mutants showed
similar patterns to HeV as well (Table 1). All NiV G mutants bound soluble B2-hFC at levels
similar to their CSE levels (Fig 1D). Western blot analysis of the NiV G mutants showed that,
again, all with the exception of S110A were expressing within cell lysates (Fig 1E), including
T119A, which was expressed poorly at the cell surface, suggesting that T119A’s reduced CSE
may be due to an alteration in trafficking to the cell surface. Altogether these results are the first
demonstration of a role for O-glycans in modulating paramyxovirus-induced membrane fusion,
and suggest this function is highly conserved among the henipaviruses.
Table 1. Fusion indices of HeV and NiV O-glycanmutants. Normalized fusion values were divided by nor-
malized CSE values for each mutant. As values for fusion and CSE for the WT proteins were by definition set
at 100%, the WT fusion index was set as 1. Hyperfusogenic mutants are defined as1.5, and hypofusogenic
mutants are defined as0.5. Hyper and hypo-fusogenic mutants are in bold. Averages are shown. Statistical
analysis was performed using a Student’s t-test. Statistically significant differences are marked with an
* (p<0.05).
Mutant CSE/Fusion (HeV) CSE/Fusion (NiV)
WTG 1 1
T103A 0.02* 0.06*
S110A 0.87 -
T114A-S115A 1.01 1.20
S116A 0.90 0.72
T117A 2.99* 2.14*
S116A-T117A 3.02* 2.79*
T119A 0 0
S129A 1.76* 2.43*
S132A 0.99 1.16
S134A-T135A 1.02 1.23
S136A-S137A 1.01 1.04
doi:10.1371/journal.ppat.1005445.t001
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G/F association is altered by O-glycan loss, but does not determine
membrane fusogenicity
Though the specifics of the HNV F and G spatiotemporal interactions are still largely
unknown, the available evidence suggests that HNV F and G interact on the cell or viral mem-
brane prior to receptor binding, after which F and G dissociate from each other, triggering F to
execute fusion (dissociation model) [38,52,53]. We tested the interactions of the HeV G and
NiV G O-glycan mutants with HeV or NiV F, respectively, through a co-immunoprecipitation
(co-IP) assay. 293T cells were co-transfected with wt HNV F and wt or mutant HNV G. After
16–20 hours cells were collected in lysis buffer and applied to a co-IP column (Miltenyi Biotec).
Cell lysates and co-IP eluates were separated by SDS-PAGE and blotted using rabbit anti-HA
(to detect G) and mouse anti-AU1 (to detect F) 1° antibodies, followed by fluorescent 2° anti-
bodies. HNV F is produced as an uncleaved precursor, F0, that is cleaved by cathepsin L upon
endocytosis into F1 and F2 subunits, linked by a disulfide bond [54,55]. The F0 (precursor) and
F1 (processed) bands are both AU1-tagged and thus visible in Western blots, resulting in two
bands for F and one for G (Fig 2). Co-IP values calculated via quantitative Western blot analy-
ses (Fig 2E) revealed that the hyper-fusogenic mutants all had decreased F0 association (0.64–
0.74 co-IP values), though this decrease in association was not observed for the F1 band, sug-
gesting that removing O-glycans from these residues may alter intracellular F/G interactions,
and to a lesser extent or not at all surface interactions (Fig 2). The nature of co-immunoprecipi-
tation assays to study membrane protein interactions, including the use of detergents and the
artificial association of membrane proteins via micelle formation, may account for the lack of
differences in G/F1 interactions for the mutants, as further discussed in our Discussion section.
Thus, even though the G/F1 interactions do not seem to be affected, it is possible that the
altered F0/G interactions suggest overall effects in the G/F interactions, which generally support
the dissociation model for HNV. These results were consistent for both the HeV G and NiV G
mutants. Most likely, however, our G/F1 interaction data is consistent with the hyper- or hypo-
fusogenic phenotypes of the O-glycan mutants not being a result of the effects of the O-glycan
mutants on F/G interactions.
Loss of specific O-glycans can affect HNV G conformations
It is possible that loss of O-glycans could affect glycoprotein conformations, so we next tested
if differing conformations correlated with the altered fusion phenotypes we observed. We have
previously generated conformational antibodies to NiV G, some of which also bind HeV G.
The first, Mab45, binds at the base of the head near the stalk, while the second, Mab26, binds
the top of the head near the receptor binding site of both NiV and HeV [49,56]. We tested the
binding of these antibodies to HNV G via flow cytometry and found that, while the majority of
the mutants had antibody binding profiles similar to those of the wt HNV G, the fusion dead
T119A mutant showed decreased Mab26 binding, suggesting that this mutant has an altered
conformation for both viruses (Fig 3A and 3B).
Mab45 and Mab26 can also measure receptor-induced conformational changes in HNV G
that are important to trigger F. We previously showed that upon receptor binding a conforma-
tional change occurs in NiV G region 9 (bound by Mab26), followed by a conformational
change in region 4 (bound by Mab45), leading to uncovering of a specific domain at the C-ter-
minus of the stalk, which triggers F. Moreover, mutants unable to fully undergo these confor-
mational changes were hypo-fusogenic, demonstrating that these conformational changes in G
are important for fusion [49]. These conformational changes can be measured by comparing
antibody binding in the absence vs. presence of soluble ephrinB2 receptor binding. With no
receptor present, Mab26 binding to G is relatively higher, but decreases as more ephrinB2 is
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added. Mab45 exhibits the opposite trend, with binding of Mab45 to G increasing upon the
addition of soluble ephrinB2 [49].
Thus we tested Mab26 and Mab45 binding to wt or mutant HNV G at 0nM and 100nM
ephrinB2. 100nM values were normalized to those at 0nM to represent the amount of increased
or decreased antibody binding in the presence of receptor. All HeV mutants showed a decrease
in Mab26 binding and an increase in Mab45 binding to some degree, suggesting the mutants
Fig 2. Associations with F are altered by O-glycan loss. A) Cell lysates of cells transfected with wt F and either wt or mutant HeV G. HeV G (top) is blotted
with rabbit anti-HA, and HeV F (bottom) is blotted with mouse anti-AU1. B) Pulldown of HeV G and co-IP of F for transfected cells. Antibody blotting was
performed as in A). C) Cell lysates of cells transfected with wt F and wt or mutant NiV G. D) Co-IP of NiV transfected cells. E) Co-IP values of HeV and NiV O-
glycan mutants, determined by densitometry. Image Lab software (Biorad) was used to measure the densitometry of Western blot bands. Co-IP values were
determined by dividing either the F0, F1, or total F densitometry values for the co-IP bands by the co-IP G densitometry values to account for any differences
in co-IP G pulldown. These values were then divided by F0, F1, or total F densitometry values for cell lysates to account for differences in F mutant
expression. Values were then normalized to those of wt HNV G. Averages are shown. N = 3. Statistically significant differences, as determined by a Student’s
t-test, are marked with an * (p<0.05).
doi:10.1371/journal.ppat.1005445.g002
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are all still able to make the conformational changes involved in fusion (Fig 3C). Interestingly
however, when the same assays were performed with the NiV G mutants, the T119A mutant
showed decreased Mab45 and Mab26 binding in 100nM ephrinB2 compared to wt G (Fig 3D),
suggesting that the hypo-fusogenicity of this mutant may in part be due to an inability to
undergo the full range of conformational changes required for fusion. These data, combined
with T119A’s decreased Mab26 binding in the absence of receptor, suggest that this mutant is
in a near post-receptor binding conformation, preventing it from undergoing the Mab45 bind-
ing enhancement indicative of a full-range conformational switch from pre to post receptor
binding conformations.
In addition, all mutants co-migrated with wt HNV G when analyzed by semi-denaturing
SDS PAGE, with all relative levels of tetramers, dimers, and monomers not significantly
affected by the loss of an O-glycan as determined by densitometry (S1 Fig), suggesting that
Fig 3. O-glycan loss can affect HNV G conformation. A & B) Normalized mAb binding to wt or mutant HeV G (A) or NiV G (B). All antibody binding levels
are normalized to the CSE of each mutant (as measured by HA levels). N = 3. C & D) Conformational changes of wt or mutant HeV G (C) or NiV G (D) as
measured by Mab45 (white) and Mab26 (black) upon the addition of 100nM ephrinB2. All values are normalized to antibody binding levels when no (0nM)
ephrinB2 was added. Averages and standard deviations are shown. N = 3. Statistically significant differences, as determined by a Student’s t-test, are
marked with an asterisk (p<0.05).
doi:10.1371/journal.ppat.1005445.g003
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O-glycan loss does not affect G oligomerization. This is important as proper oligomerization is
critical for glycoprotein function, and the G stalk is an important determinant of G oligomeri-
zation [16,45]. Overall, the majority of the O-glycan mutants’ fusion phenotypes were not due
to aberrant G conformations or abilities to undergo receptor-induced conformational changes,
with the exception of mutant T119A.
Loss of O-glycans on HNV G can affect HNV F virion incorporation and
viral entry in a pseudotyped viral system
As we found that loss of O-glycans modulated cell-cell fusion, we next tested if this affected
viral entry, using a validated BSL2 pseudotyped virus infection assay [14]. Vesicular stomatitis
virus (VSV) virions containing a Renilla luciferase gene in place of the VSV glycoprotein G
gene, and expressing HNV wt F with either wt or mutant HNV G on the outer membranes
were created as described previously [14]. These pseudotyped virions were tested for viral entry
using a Renilla luciferase reporter assay. Vero cells were infected with the pseudotyped virions
and incubated for 2 hours at 37°C. Growth media was then added, and at 18–24 hours post
infection the cells were collected, lysed, and luminescence was determined. Relative light units
(RLU), representing viral entry for each of the mutants, were compared to those of wt HNV G.
Western blot analysis of pseudotyped virion lysates were also performed to assess protein
incorporation levels.
Remarkably, Western blot analysis showed that, although G incorporation for each of the
HeV Gmutants was similar to wt G, F incorporation was reduced and F processing was
enhanced for all G mutants except T119A (Fig 4A). Densitometry confirmed this observation;
all mutants except for T119A incorporated HeV F at levels only 19–24% of that observed for
wt pseudotyped virions and increased processing of F, as determined by the ratio of F1/total F,
which was 86–99% for the mutants as compared to 54% for wt pseudotype virions (Fig 4B).
Viral entry assays showed that all G mutants displayed reduced entry levels as compared to wt
G, once again with the exception of T119A (Fig 4C), even though we would expect the three
hyper-fusogenic mutants to enter at levels higher than that of wt HeV G. Reduced pseudotyped
virion HeV F incorporation levels likely contribute to the decreased viral entry levels. To our
knowledge, this is the first report of a paramyxovirus HN, H, or G mutant affecting F incorpo-
ration into virions and thus viral entry, or affecting F processing. It is possible that loss of an
O-glycan therefore affects intracellular F/G interactions and/or glycoprotein trafficking, as well
as F processing, consistent with our co-IP results (Fig 2). It is noteworthy that the effect of G
O-glycan mutants on F processing was not observed in cell lysates (Fig 2). Additionally, flow
cytometry using a variety of anti-F antibodies revealed no significant difference in F cell surface
expression in the presence of HeV or NiV G (S2 Fig), a finding that also suggests that the
altered interactions observed by co-IP (Fig 2) were not due to differences in F cell surface
expression.
Interestingly, Western blot and viral entry assays of the NiV pseudotyped virions did not
reveal the same phenotypes. All pseudotyped virions had similar levels of NiV F as assessed by
Western blot analysis (Fig 5A) and by densitometry (Fig 5B), and with the exception of T119A,
which had less G incorporation, had viral entry values similar to that observed for wt G (Fig
5C). F processing, however, was still altered (Fig 5A and 5B). The hyper-fusogenic mutants
T117A, S116A-T117A, and S129A all had higher processing (F1) levels (69%, 55%, and 55%,
respectively), whereas the wt (39%) and hypo-fusogenic mutants T103A and T119A had lower
(27% and 29%) processing (F1) levels (Fig 5B). These data further corroborate that HNV G O-
glycan loss can affect HNV F in pseudotyped virions, and implies that the mechanisms may
differ between HeV and NiV, since F incorporation was affected more for HeV than for NiV.
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Since equivalent mutant NiV pseudotyped virions are able to enter cells at wt levels with proper
F incorporation, the data from NiV pseudotyped virions also further supports the explanation
that reduced F incorporation is responsible for the reduced pseudotyped viral entry levels
observed in the HeV mutants, at least to some degree. Other potential mechanisms, such as the
contribution of O-glycans to the stability of virions, are further explored in the Discussion.
Interestingly, the S129A mutant also had less G incorporation (Fig 5A), though it was still able
to enter cells at levels similar to wt G, suggesting that with full G incorporation this mutant
may have had entry levels greater than the wt G pseudotyped virions.
In summary, we have found that HNV O-glycans had roles in cell-cell fusion, G/F interac-
tions, G conformation, pseudotyped viral entry, and F incorporation and processing in pseudo-
typed virions. These important viral glycoprotein phenotypes were mostly conserved among
HeV and NiV, but some important differences were observed between NiV and HeV O-glycan
functions.
Fig 4. Loss of O-glycans in HeV G affect HeV F incorporation and processing in pseudotyped virions, affecting viral entry. A) Western blot of HeV/
VSV viral lysates. HeV G (top panel) and HeV F (bottom panel) were detected as described in Fig 2. B) F incorporation and F processing of the HeVmutant
pseudotyped virions determined by densitometry. F incorporation values were normalized to those of wt HeV. F processing was measured by the ratio of F1/
(F0+F1) for HeV pseudotyped virions. N = 3. Statistically significant differences, as determined by a Student’s t-test, are marked with an * (p<0.01). C) Viral
entry of HeV/VSV virions at log dilutions of viral input. Values for the mutant virions are compared to wt HeV values. Virions expressing only HeV G (no HeV
F) were used as a negative control. Averages and standard deviations are shown. N = 3.
doi:10.1371/journal.ppat.1005445.g004
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Discussion
Viral O-glycans remain understudied, and the present study is the first to show functions for
paramyxoviral O-glycans. In mammalian cells, O-glycans have functions in receptor binding,
cell-cell interactions, cellular trafficking, and immune system regulation [2–4]. Viruses use gly-
cosylation for protein trafficking, signaling, folding, immune evasion, and receptor interactions
[1], but the majority of these functions have been described for N-glycans. The lack of clear O-
glycosylation prediction motifs, and the fact that utilization of some O-glycan sites can affect
O-glycosylation of neighboring sites [21], makes analysis of specific O-glycan functions much
more complex. O-glycans are present on HIV, SIV, Marburg, MHV, and vaccinia virus glyco-
proteins [28–32] but their functions are still unknown. While some studies have shown that O-
glycans are involved in immune evasion, receptor binding, plaque formation, and possibly cell
detachment [22,25,27], this has not been described for paramyxoviruses, although prior work
has shown that O-glycans do not play roles in RSV-G oligomerization [33] nor NDV receptor
Fig 5. Loss of O-glycans in NiV G does not affect NiV F incorporation in pseudotyped virions, but affects NiV F processing and pseudotyped viral
entry. A) Western blot of NiV/VSV viral lysates. NiV G (top panel) and NiV F (bottom panel) were detected as described in Fig 2. B) F incorporation and F
processing of the NiV mutant pseudotyped virions determined by densitometry. F incorporation values were normalized to those of wt NiV. F processing was
measured by the ratio of F1/ (F0+F1) for NiV pseudotyped virions. N = 3. Statistically significant differences, as determined by a Student's t-test, are marked
with an * (p<0.01). C) Viral entry of NiV/VSV virions at log dilutions of viral input. Values for the mutant virions are compared to wt NiV values. Pseudotyped
virions expressing only NiV G (no NiV F) were used as a negative control. Averages and standard deviations are shown. N = 3.
doi:10.1371/journal.ppat.1005445.g005
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binding [34]. The present work is the first to show functions for paramyxoviral O-glycans, and
one of only a handful of studies demonstrating functions of O-glycans for any virus.
Interestingly, with one exception, all the O-glycans identified in HeV were found in the G
stalk domain [50]. Though it is still unclear which regions of HNV G are necessary for fusion,
there is strong evidence that the HNV G stalk plays a central role in F triggering. Headless
mutants can trigger fusion in PIV5, MeV, NDV, MuV, and NiV [46–49], and disruption of the
stalk using various methods perturbs fusion in NiV, MeV, PIV5, and NDV [43–45,57–60].
Here we demonstrated that loss of O-glycans from the stalk of a paramyxovirus attachment
protein affects fusion, and in all cases but one, this was not due to altered CSE or receptor bind-
ing levels (Fig 1B and 1D). Interestingly, previous studies showed that removal of certain N-gly-
cans in HNV F or the G head resulted in hyper-fusogenicity [12,14–16], while removal of one
N-glycan from the G stalk resulted in hypo-fusogenicity [15,16], without affecting receptor
binding. Our study demonstrates that O-glycans in the stalk are capable of both up- or down-
modulating fusion.
There are currently two different interaction models for the two paramyxovirus glycopro-
teins. In the association model proposed for PIV5 and NDV, for example, F and HN do not
interact at the cell surface until receptor binding occurs, after which HN/F association occurs
and F is triggered. In contrast, in the dissociation model proposed for MeV, NiV, and HeV, H/
F or G/F interact prior to receptor binding; after which the glycoproteins dissociate from each
other, triggering F and allowing fusion [38,52]. Reportedly, for HNV hyper-fusogenic and
hypo-fusogenic mutants have shown decreased or increased F association, respectively, while
receptor binding resulted in partial G/F dissociation [14,56,61], findings that support the disso-
ciation model. Our co-IP data further support this dissociation model for HNV. The hyper-
fusogenic mutants had decreased F interactions with F0, though this decrease did not extend to
the F1 subunit (Fig 2), suggesting that the altered interactions may only be with the immature F
protein. These results present the possibility that the O-glycans themselves are directly
involved in the association between G and F, though these altered interactions are unlikely to
account completely, if at all, for the observed fusion phenotypes since G/mature F (F1) interac-
tions were not significantly altered. Additionally, the lack of difference in G/F1 association
between mutants suggests that fusion phenotypes may be independent of F/G association lev-
els. It is also possible, however, that G/F1 interactions are altered but not detectable via co-IP.
Since co-IP relies on the use of detergents that may alter protein conformations and therefore
interactions, results obtained by co-IP are not entirely conclusive. In addition, co-IP can’t dis-
tinguish pre vs post-fusion forms of the F protein. Our results, therefore, present the possibility
that the observed fusion phenotypes are independent of F/G associations, but it is also possible
that differences in mature F/G surface interactions are too small or transient to be observed by
co-IP. New methodologies may be needed assess such interaction differences.
Mutation of a single O-glycan addition site in the majority of mutants did not alter protein
conformation nor the conformational change capabilities necessary for fusion triggering [49].
The exception was mutant T119A, for which both HeV and NiV G bound Mab26, which
detects a pre-receptor binding conformation, at reduced levels (Fig 3). This same mutant in
NiV also failed to show enhancement of Mab45 binding upon addition of ephrinB2, suggesting
that this mutant may already be in a post-receptor binding conformation at least partially, con-
tributing to the loss-of-fusion phenotype. These data also suggest that retention of G in a pre-
receptor binding conformation is important for its F-triggering capability. The HeV T119A
mutant still showed enhanced, albeit less than wt HeV G, Mab45 binding after ephrinB2 addi-
tion, suggesting that, while HeV T119A may have an altered conformation, implied by
decreased Mab26 binding, this conformational change may not be as functionally detrimental
as that of NiV T119A. Even though HeV and NiV G are highly homologous, this hints at
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conformational differences between the two G glycoproteins. This may also relate to the differ-
ing CSE levels of these two mutant proteins (87% for HeV and 36% for NiV T119A) (Fig 1B
and 1D). It is also noteworthy that loss of an O-glycan did not affect oligomerization for any of
these mutants, an interesting finding since O-glycans are in the stalk domain of HNV G, which
is crucial for G oligomerization [45].
Although cell-based assays, such as cell-cell fusion, CSE, ephrinB2 binding, F interactions,
and conformational change capabilities, yielded similar results for HeV and NiV, we observed
more marked differences in pseudotyped virion infections when the O-glycan mutant G pro-
teins were expressed. The NiV G mutant virions all displayed pseudotyped viral entry of Vero
cells similar to that observed for wt NiV G (Fig 5C), yet most HeV G mutant pseudotyped viri-
ons showed reduced viral entry (Fig 4C). Additionally, pseudotyped virions with mutant HeV
G had reduced HeV F incorporation and altered F processing, evidenced by little to no F0 pres-
ent in the viral lysates (Fig 4A and 4B). It is remarkable that loss of O-glycans from HeV G
affects F incorporation and processing, and therefore viral entry. Since F may be a driver of
viral budding [62], this finding has implications not only for fusion triggering but also for viral
assembly and budding, viral particle release, and therefore viral infectivity. O-glycans have
been shown to play roles in protein-protein interactions for non-viral proteins [4]. Therefore,
it is possible that loss of G O-glycans affects intracellular G/F interactions, thus affecting viral
incorporation of both glycoproteins into pseudotyped virions. This is particularly interesting
because HeV G and F have been shown to traffic to the cell surface at different rates [63]. Fur-
ther investigation is needed to determine exactly how mutations in HeV G have such a pro-
nounced effect on HeV F incorporation, particularly in pseudotyped virions, and why this
same phenomenon was not observed for NiV G.
Unlike their HeV counterparts, NiV mutant pseudotyped virions incorporated NiV F and
also entered cells at wt levels (Fig 5A and 5B), yet F processing was still altered. The hyper-fuso-
genic mutants, especially T117A and S116A-T117A, showed more efficient F processing (Fig
5A and 5B). Since F1 is the mature form of F, more efficient F processing may induce hyper-
fusogenicity for these mutants. Since F must be re-internalized for processing and cleavage,
loss of specific O-glycans could affect endocytosis of F [54,55]. The hyperfusogenic mutants,
for example, showed less interaction with F0 via co-IP (Fig 2), which may enable F endocytosis
for cleavage into F1 and F2 more easily than the wt G or the hypo-fusogenic mutants with
stronger F interactions, rationalizing the increase in F processing in the hyperfusogenic mutant
virions. Our results demonstrating that HNV Gmutants affect F processing are unprecedented
and unexpected, warranting further mechanistic studies.
Furthermore, premature F triggering on viral surfaces may have also occurred with the
HNV pseudotyped virions. Even though the NiV hyper-fusogenic pseudotyped virions entered
cells at wt levels (Fig 5C), we would expect increased entry for the hyper-fusogenic mutants
compared to wt G. Premature F triggering has been observed and offered as an explanation for
differences between cell-cell fusion and pseudotyped viral entry levels for a headless NiV G
mutant [49]. As virions are incubated at 37°C in cell supernatants prior to collection, F and G
have the opportunity to interact prematurely, triggering F before a target membrane is present.
The prematurely triggered F is then unable to trigger fusion once the virions attach to target
cells. Since our co-IP results show that hyper-fusogenic mutants already have a lowered associ-
ation with F, potentially releasing F more readily for fusion, this may explain why the hyper-
fusogenic mutant virions would be most affected by premature F triggering. Supporting this
notion, pseudotyped virions produced at 32°C instead of 37°C to hinder premature F triggering
regained F incorporation and viral entry levels similar to those of the wt pseudotyped virions
(S3 Fig), though we acknowledge that there are other potential cellular factors that may have
been altered at the lower temperature.
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It should be noted, however, that here we have used a pseudotyped viral system instead of
actual henipaviruses. While this pseudotype system has been used extensively in previous stud-
ies [14–16,49,64], there are limitations to this approach. Though the pseudotyped virions are
expressing the HNV glycoproteins on the viral membrane, they still contain the VSV genome
and other VSV proteins. The presence of the VSV matrix protein in place of the HNV matrix
protein, a protein known to affect viral processes such as budding [65], may alter virion charac-
teristics. It is also possible that interactions occur between the VSV matrix protein and HNV F/
G, since it has been suggested that the HNV matrix protein may interact with each of these gly-
coproteins [62,66]. The viral morphology of the pseudotyped virions is that of the bullet-
shaped VSV, instead of the pleomorphic shaped paramyxoviruses, a factor that may also affect
viral particle formation and entry. Thus it is possible that the phenotypes observed in the pseu-
dotyped NiV/VSV and HeV/VSV systems would not translate 100% to actual HNV virions.
Due to the BSL4 and reverse genetics requirements to assess these differences with actual HeV
or NiV, however, the pseudotyped viral system is an effective surrogate system that provides
valuable insight, and further BSL4/reverse genetics studies are warranted.
Both N and O-glycans have been shown to shield viruses against antibody neutralization.
O-glycans play a role in shielding the gammaherpesvirus BoHV-4 [22], while loss of specific
HeV and NiV N-glycans increased virus susceptibility to antibody neutralization [14–16].
Based on these findings, we hypothesized that loss of O-glycans from HNV G would enhance
antibody neutralization sensitivity. Antibody neutralization studies, however, showed no anti-
body neutralization shielding effects (S4 Fig), highlighting a difference in function between N
and O-glycans at least for HNV. It is possible that this functional difference is due to the differ-
ence in glycan size, as O-glycans are typically smaller than N-glycans [67]. It is also possible
that loss of all O-glycans simultaneously, as performed for BoHV-4 [22] would result in
increased antibody neutralization susceptibility, but that loss of a single (or two) O-glycan
alone is insufficient to have this effect. Alternatively, this part of the G stalk may not be critical
for HNV antibody neutralization.
Since it is known that O-glycosylation at one site can affect the glycosylation of neighboring
sites [21], mass spectrometry would be needed to determine if loss of an O-glycan at one site
affects addition of O-glycans at other sites for our set of O-glycan mutants. Although these
studies require high levels of purified recombinant viral glycoproteins, glycobiology expertise,
and time of analysis (likely a 1–2 year project), as evidenced by the scarcity of O-glycan studies
currently published for viral glycoproteins, this would be a worthwhile future study. The func-
tions of O-glycans observed in the present study, however, are accurate regardless of whether
or not neighboring O-glycan sites are affected by loss of O-glycans at our specific mutated
sites.
In summary, we have identified multiple novel functions of paramyxovirus O-glycans in
HNV, including strong modulation of cell-cell fusion, and effects on G/F interactions, G con-
formation, receptor-induced G conformational changes, and quite remarkably, F processing
and F incorporation into pseudotyped virions. These novel O-glycan functions shed light on
the paramyxovirus-induced membrane fusion mechanisms, reveal a new function for G in F
interactions, incorporation into virions, and processing, and contribute to our limited knowl-
edge of the functions of viral O-glycans. It remains to be determined if the high densities of O-
glycans and their multiple functions on the stalks of the attachment glycoproteins are con-
served among all paramyxovirus genera. Moreover, differences in host cell glycosylation
machinery may affect the extent of O-glycosylation or O-glycan structures, so that virions pro-
duced in different types of host cells may be differentially glycosylated. The current work paves
the way for future functional studies of O-glycans for other paramyxoviruses and other viral
families.
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Materials and Methods
Expression plasmids
Codon optimized HNV G and HNV F genes tagged with HA or AU1 tags, respectively, were
expressed in PCDNA3.1 or PCAGGS plasmids as previously described [18]. Alanine substitu-
tion mutants were created by site-directed mutagenesis of HNV G using a QuikChange kit
(Stratagene). Mutations were confirmed by sequencing the entire open reading frame.
Cell culture
293T (ATCC) and PK13 (ATCC) cells were cultured in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum (FBS). Vero (ATCC) cells were cultured in minimal essential
medium alpha with 10% FBS.
Cell surface expression, ephrinB2 and antibody binding by flow
cytometry
Production of rabbit anti-NiV G monoclonal antibodies has been previously described [56].
Binding of rabbit monoclonal antibodies, mouse anti-HA, or soluble B2-hFc to HNV G wild
type (wt) or mutants was measured by flow cytometry. 293T cells were transfected with 2 μg wt
or mutant HNV G expression plasmids and collected 20–24 hours post-transfection. Collected
cells were incubated 1 hour at 4°C with 1° antibodies diluted 1:100 to 1:1000 and washed three
times in FACS buffer (1% FBS with PBS). Cells were next incubated with fluorescent anti-
human, anti-mouse, or anti-rabbit Alexa Fluor 647 or 488 antibodies (Life Technologies, NY)
diluted 1:200 for 30 min at 4°C, followed by an additional two washes. Cells were fixed in 0.5%
PFA and read on a flow cytometer (Guava easyCyte8 HT, EMDMillipore, MA). B2-hFc was
used at a 100 μM concentration. For conformational change assays PK13 cells were transfected
with wt or mutant HNV G expression plasmids. 0 or 100 μM soluble ephrinB2 was added and
cells were incubated for 15 min at 4°C. Mab45 or 26 was added at concentrations specified
above and cells were incubated 1 hour at 37°C. 2° antibody, fixation, and cytometer reading
were as listed above [49,56].
Cell-cell fusion quantification
293T cells grown in 6 well plates were transfected at 70–90% confluency with HNV F and
either HNV G or G mutant expression plasmids (1:1 ratio, 2 μg total DNA) using BioT or tur-
bofectamine transfection reagent. 18 hours post-transfection cells were fixed in 0.5% parafor-
maldehyde and syncytia counts were performed under the microscope (200x), with a
syncytium being defined as four or more nuclei within a single cell. Five fields per well were
counted [14,49].
Western blot analysis
Transfected cells or pseudotyped virions expressing HNV G wt or mutants with or without
HNV F were lysed in RIPA buffer (Millipore) supplemented with complete protease inhibitor
(cOmplete Mini, Roche). Lysates were heated at 65°C for 10 minutes and run on a 10% gel for
SDS-PAGE analysis. Immunoblots were performed using mouse anti-AU1 or rabbit anti-HA
at 1:250 to 1:2000 dilutions. Fluorescent 2° antibodies were diluted 1:1000–1:2000 and blots
were imaged on a Li-Cor Odyssey fluorimager.
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Co-immunoprecipitation
Cells transfected with HNV wt or mutant G expression plasmids were lysed in lysis buffer (Mil-
tenyi Biotec). Cell lysates were incubated with 40ul of anti-HA microbeads at 4°C for 30 min-
utes with rotation. Lysates were purified and eluted over μ columns (Miltenyi Biotec). PAGE
was used for cell lysates and column elutions using a 10% gel. F and G proteins were detected
by Western blot analysis, as detailed above.
Pseudotyped virus production and quantification
Pseudotyped virions containing HNV F with wt or mutant HNV G were manufactured as pre-
viously described [14,39]. Briefly, 15cm plates of 293T cells were transfected at 37°C with HNV
F and wt or mutant HNV G expression plasmids at a 1:1 ratio. After 8 hours the transfection
media was switched to growth media. After an additional 16 hours the cells were infected with
recombinant VSV-ΔG-rLuc. 2 hours later the infection media was removed and replaced with
growth media. 24 hours after infection virions were harvested from cell supernatants using
ultracentrifugation, resuspended in NTE with 5% sucrose, and stored at -80°C. Viral RNA was
extracted using a QIAamp viral RNA mini kit (Qiagen, CA) and the resulting viral RNA was
reverse transcribed using a SuperScriptIII First-Strand Synthesis System for RT-PCR (Invitro-
gen, NY). Quantitative PCR (qPCR) was performed using a Taqman probe for the VSV
genome to quantify viral copy number. For virions produced at 32°C, all transfections and viral
infections were carried out at 37°C, and plates were switched to 32°C upon addition of new
growth media.
Pseudotype viral infection assays
Vero cells were infected with tenfold dilutions of pseudotyped virus particles in infection buffer
(PBS + 1% FBS) and incubated for 2 hours at 37°C. After 2 hours growth media was added. 18–
24 hours after infection cells were lysed and an Infinite M100 microplate reader (Tecan Ltd)
was used to measure luciferase activity.
Antibody neutralization assays
Pseudotyped virions were incubated for 20 min in infection buffer (PBS + 1% FBS) in the pres-
ence of varying dilutions (10-2 to 10-7) of anti HNV G polyclonal antibody. The virus/antibody
mixture was added to Vero cells and incubated for 2 hours, after which growth media was
added and the cells were incubated an additional 18–24 hours. Viral infection was then mea-
sured as described above.
Supporting Information
S1 Fig. Loss of O-glycans does not affect oligomerization. Semi-denaturing SDS-PAGE
Western blots of A) HeV and B) NiV cell lysates. Tetramers, dimers, and monomers are noted.
C&D) Percentages of tetramers, dimers, or monomers of HeV G (C) or NiV G (D) mutants, as
measured by densitometry. N = 3. No statistical differences were detected from wt G (p>0.05).
(TIF)
S2 Fig. Cell surface expression of HNV F is not affected by HNV G expression. Cell surface
expression values of A) HeV F and B) NiV F in the presence of G, as measured by flow cytome-
try. 834 and 835 are polyclonal antibodies that bind both HeV and NiV F. 2–36 is an anti-HeV
F specific monoclonal antibody. HNV G values were measured using an HA tag. All values are
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normalized to wt HeV or NiV F or G. Averages and standard deviations are shown. N = 5.
(TIF)
S3 Fig. Mutant pseudotyped virions produced at 32°C infected cells at levels similar to wt
HNV G. Infection levels of HeV/VSV (top) and NiV/VSV (bottom) virions produced at 32°C
at log dilutions of viral input. Virions expressing only HNV G (no HNV F) were used as a neg-
ative control. Averages and standard deviations are shown. N = 3.
(TIF)
S4 Fig. O-glycans do not affect antibody neutralization levels.Neutralization of A) pseudo-
typed HeV/VSV or B) pseudotyped NiV/VSV virions at log dilutions of antibody. A panel of
four different polyclonal antibodies was used. Neutralization curves of one representative poly-
clonal antibody per virus are shown, with averages and standard deviations. N = 3.
(TIF)
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